It typically presents 3 months to 2 years post-transplant with symptoms such as worsening hypertension, hypokalemia, and kidney function decline when treated with angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARBs). The gene discussed is ACE; the disease is Hypertension.